Thyroid eye disease affects roughly 30–50% of people with Graves' disease. That estimate comes from a 2026 review in *Autoimmunity Reviews*. It covers how thyroid eye disease develops, its signs, and current treatments. This was a review of existing knowledge, not a new treatment study. Graves' disease involves the immune system attacking the body and causing an overactive thyroid. In thyroid eye disease, the immune system attacks tissues behind the eyes. The condition usually affects both eyes. During active disease, signs include redness, swollen eyelids, and sensitivity to light. Eyes may bulge, and people may see double. Severe cases can damage the nerve that carries signals from the eye. The review says these vision-threatening cases require urgent treatment. Care includes controlling the overactive thyroid and treating the eyes. Treatments can also calm the immune system. The review highlights teprotumumab, a drug that targets signals involved in the disease. It can reduce eye bulging and signs of active disease. However, the supplied summary gives no numbers for those improvements. Other drugs are still being studied. For our TSH (Thyroid-Stimulating Hormone) community, this adds context to bloodwork tracking. The 30–50% estimate applies to Graves' disease, not everyone with an unusual thyroid result. The review does not give a blood level that predicts eye disease. Pairing dated bloodwork with notes about eye symptoms could help members compare experiences. Those notes can add context without treating one number as the whole story. If you track thyroid bloodwork, what eye changes have you noticed alongside your results?